H. Lundbeck AS (FRA:LDBA) GF Value Rank: 9 (As of Jul. 14, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LDBA H. Lundbeck AS FRA:LDBA
84 GF Score
Price €5.63
GF Value €6.21
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is H. Lundbeck AS GF Value Rank?

H. Lundbeck AS FRA:LDBA -1.83% 84 GF Value Rank is 9 as of Jul. 14, 2026, which is at its 10-year median of 9.00. GuruFocus rates FRA:LDBA with a GF Score™ of 84/100 and a GF Value™ of €6.21 (Fairly Valued). The stock has 3 warning signs investors should review.

H. Lundbeck AS has the GF Value Rank of 9.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


H. Lundbeck AS GF Value Rank Related Terms


FRA:LDBA vs ZTS, UTHR, VTRS: GF Value Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS GF Value Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's GF Value Rank distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's GF Value Rank falls into.


FRA:LDBA
84GF Score
H. Lundbeck AS FRA:LDBA
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 9 mean?
H. Lundbeck AS (FRA:LDBA) has a GF Value Rank of 9 as of Jul. 14, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on H. Lundbeck AS and its competitors. This is near median its historical median of 9.00. Over the past decade, H. Lundbeck AS's GF Value Rank has ranged from 2.00 to 10.00.
Is H. Lundbeck AS's GF Value Rank too high?
H. Lundbeck AS's current GF Value Rank of 9 is near median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, H. Lundbeck AS has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's GF Value Rank compare to ZTS and UTHR?
H. Lundbeck AS's GF Value Rank of 9 can be compared against companies in the Drug Manufacturers industry. Historically, H. Lundbeck AS's own GF Value Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Drug Manufacturers company?
A good GF Value Rank depends on the Drug Manufacturers industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on H. Lundbeck AS and its competitors. H. Lundbeck AS's current GF Value Rank is 9, which is near median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (FRA:LDBA) is currently considered Fairly Valued. The stock's GF Value™ is €6.21, compared to a current price of €5.63 — trading 9.4% below its estimated fair value. The current GF Value Rank is 9, which is near median its 10-year median of 9.00. H. Lundbeck AS's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For H. Lundbeck AS (FRA:LDBA), the current GF Value Rank is 9 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of €5.63 is trading 9.4% below its estimated GF Value™ of €6.21. GuruFocus considers H. Lundbeck AS to be Fairly Valued.

Key valuation signals for FRA:LDBA:

  • GF Value Rank: 9 (near median its 10-year median of 9.00)
  • GF Value™: €6.21 vs. price of €5.63 (9.4% below fair value)
  • GF Score™: 84/100 with 3 warning signs

No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
84GF Score

Get the complete analysis for FRA:LDBA

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.63
Price
€6.21
GF Value